Ipca Laboratories Limited share price
NSE: IPCALAB · ISIN INE571A01038
Key numbers
- Market cap
- ₹ 50,000 Cr
- Current price
- ₹ 1,970.80
- 52-week high / low
- ₹ 2,038 / 1,252
- Stock P/E
- 38.1
- Book value
- ₹ 317.8
- Dividend yield
- 0.30%
- ROCE
- 19.2%
- ROE
- 15.2%
- Debt to equity
- 0.10
- Sales growth (3 yrs)
- 15.5%
- Profit growth (3 yrs)
- 34.3%
- 1-year return
- 41.3%
About Ipca Laboratories Limited
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetes, diabetology, emollients/protectives, fever, gastroenterology, haematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, regenerative, respiratory, rheumatology, and urology. The company also exports its products to Europe, Africa, the Americas, rest of Asia, the Commonwealth of Independent States, and Australasia. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 2,309 | 2,557 | 2,393 | 2,388 | 2,788 |
| Operating profit | 416 | 545 | 533 | 484 | 670 |
| Net profit | 233 | 283 | 326 | 299 | 402 |
| EPS (₹) | 9.19 | 11.14 | 12.86 | 11.79 | 15.84 |
Concall summary (2026-08-17)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- Our domestic formulation business for Q1 FY27 has delivered growth of 13% to around INR1,082 crores as against INR961 crores in Q1 FY26.
- Overall export business has delivered growth of around 34% for Q1 FY27 to around INR603 crores from INR450 crores in Q1 FY26.
Growth & demand
- Market share has marginally improved to around 2.08% as against 2.07% in March '26.
- Our chronic segment growth is around 17.2% and acute growth is around 8.9%.
Margins & costs
- Overall consolidated EBITDA margins has improved to 22.88% for Q1 FY27 f rom 18.39% for Q1 FY26.
- And stand-alone EBITDA margins for Ipca has improv ed to 26% in Q1 FY27 to around 23.82% from INR2 around INR557 crores from INR416 crores in last financial year, an improvement of almost around 34%.
Capex & expansion
- Capacity expansion will also be needed and that's g oing on right now because we need lot of capacity for European markets and U.S. market.
- Biotech is one area where also capexs are going on in terms of further increasing R&D investments, R&D assets and at plant level also those kind of capexs are there.
Balance sheet & cash
- Currently, the debt may be around INR193 crores in books.
- And I think by this year-end, what we will have is INR70 crores of term loan debt outstanding and that will be repaid completely in the next financial year.
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.